{"id":7942,"date":"2022-06-02T07:16:00","date_gmt":"2023-06-06T07:16:45","guid":{"rendered":"https:\/\/www.salesforce.com\/?p=7942"},"modified":"2023-06-15T13:49:37","modified_gmt":"2023-06-15T13:49:37","slug":"patient-centric-innovation-in-pharmaceuticals-industry","status":"publish","type":"post","link":"https:\/\/www.salesforce.com\/in\/blog\/patient-centric-innovation-in-pharmaceuticals-industry\/","title":{"rendered":"Why the Next Era in Pharmaceuticals Will Be About Patient-Centric Innovation"},"content":{"rendered":"\n

We tend to think of healthcare in terms of patient-doctor engagement. A patient visits the doctor, gets a prescription, takes the medicine, and feels better. But behind the scenes, there are so many touchpoints that have to be seamlessly orchestrated to ensure that the patient receives the right treatment at the right time. Here\u2019s a broad breakdown of those components.<\/p>\n\n\n\n

\"From <\/p>\n\n\n\n

For details on this infographic, please click here.<\/a> <\/p>\n\n\n\n

Let\u2019s look at the first set of participants along this healthcare continuum \u2014 pharma or life sciences companies. <\/p>\n\n\n\n

COVID-19 puts pharma in the spotlight <\/span> <\/h2>\n\n\n\n

While the pharma industry has always been important to health and wellness, its impact was especially evident during the COVID-19 breakout. All eyes were on pharma companies as they raced against time to develop medicines that would treat the disease, along with vaccines that would control it. Terminology around molecules, bio-molecules, DNA, and m-RNA recombinants became part of our collective vocabulary.<\/p>\n\n\n\n

Globally, the first COVID-19 vaccine to be approved for emergency use was developed by an American pharma giant with a German biotech firm. Soon after that, India\u2019s indigenously developed COVID-19 vaccine was cleared for use along with another licensed vaccine developed in the UK. The latter accounts for over two-thirds of the vaccinations<\/a> delivered in India thus far.<\/p>\n\n\n\n

For each of the competing vaccines, the success of the molecule-to-market cycle depended on multiple factors. Those vaccine developers that had proactively aligned their people, processes, and technology were able to serve humanity quicker and better than the competition.<\/p>\n\n\n\n

Accelerating the pace of pharmaceutical innovation <\/span> <\/h2>\n\n\n\n

A paper by Intouch Group and DHC Group<\/a> states that \u201cCOVID has presented \u2018big pharma\u2019 with a goodwill generation opportunity that the industry has not seen in a long time. Pharma companies have a unique chance to build on this position of trust.\u201d<\/p>\n\n\n\n

Now is the time for pharma companies to take centre stage. They\u2019ve already set the bar high through their record-breaking pace of innovation and cross-industry collaboration over the past two years. But can they sustain this level of innovation in a post-Covid world? We\u2019ve heard from many of our customers that the industry\u2019s inability to keep up with tech acceleration is a top concern.<\/p>\n\n\n\n

Innovation, as we saw during the development of the Covid vaccines, requires better data access and stronger technology. A KPMG survey<\/a> of CIOs in the pharma sector found that the top data priorities include:<\/p>\n\n\n\n